UVA and Nitric Oxide: The Role of Sunlight in Systemic Blood Pressure Regulation

Overview

For decades, the bio-medical discourse surrounding solar exposure has been dominated by two competing narratives: the synthesis of Vitamin D and the risk of cutaneous oncogenesis. However, a profound paradigm shift is underway, spearheaded by pioneering research within the UK, most notably from the University of Southampton and the University of Edinburgh. This research elucidates a critical, non-canonical pathway wherein ultraviolet A (UVA) radiation acts as a potent regulator of systemic arterial blood pressure. At INNERSTANDIN, we recognise that the skin is not merely a passive barrier but a sophisticated neuroendocrine organ capable of modulating cardiovascular haemodynamics through the photo-catalysed release of nitric oxide (NO).

The mechanism is elegantly complex. The human dermis and epidermis contain significant reservoirs of nitrogen oxides—specifically nitrate ($NO_3^-$), nitrite ($NO_2^-$), and S-nitrosothiols—at concentrations far exceeding those found in the systemic circulation. Upon exposure to UVA radiation (320–400 nm), these sequestered metabolites undergo non-enzymatic photo-reduction and photo-dissociation. This process mobilises nitric oxide into the dermal vasculature, where it diffuses into the smooth muscle cells of the arterial walls, activating soluble guanylyl cyclase and inducing potent vasodilation. The result is a measurable reduction in peripheral vascular resistance and a subsequent decline in systolic blood pressure.

Crucially, this phenomenon is independent of Vitamin D synthesis, which is primarily driven by the UVB spectrum. Research published in the *Journal of Investigative Dermatology* (Liu et al., 2014) demonstrated that healthy volunteers exposed to UVA equivalent to thirty minutes of natural sunlight experienced a significant drop in blood pressure and an increase in circulatory NO metabolites, while sham-exposed controls remained baseline. In the context of the United Kingdom, where hypertension remains a primary driver of cardiovascular morbidity, the implications of this photobiological pathway are staggering. Seasonal fluctuations in blood pressure, which characteristically peak during the light-deficient British winter, correlate precisely with the availability of solar UVA, suggesting that "sunshine-induced" vasodilation is a fundamental requirement for optimal cardiovascular homeostasis.

By exposing the biological reality that sunlight is a systemic circulatory regulator, INNERSTANDIN challenges the reductionist "avoidance-only" dermatological models. We must reconcile the risks of UV-induced DNA damage with the systemic necessity of NO mobilisation. Without adequate UVA exposure, the cutaneous nitrogen stores remain inert, potentially contributing to the prevalence of essential hypertension in higher latitudes. This section explores the molecular kinetics of this transition, proving that the sun’s influence reaches far deeper than the basal layer of the skin.

The Biology — How It Works

To comprehend the cardiovascular implications of solar exposure, one must look beneath the epidermal surface to the skin’s role as a sophisticated reservoir for nitrogen oxides. While conventional dermatology has historically focused on the mutagenic potential of ultraviolet radiation (UVR), research pioneered by the University of Southampton and the University of Edinburgh—notably by Feelisch and Weller—has exposed a profound regulatory mechanism that links UVA (320–400 nm) exposure to systemic haemodynamics. At INNERSTANDIN, we recognise that the skin serves as an autonomous endocrine organ, storing nitric oxide (NO) metabolites in concentrations nearly tenfold higher than those found in the systemic circulation.

The primary biological mechanism is predicated on the photolytic liberation of NO from pre-existing dermal stores. Specifically, the dermis and epidermis contain significant quantities of nitrate ($NO_3^-$), nitrite ($NO_2^-$), and S-nitrosothiols (RSNOs), such as S-nitrosoglutathione. When UVA photons penetrate the dermal layers, they trigger the non-enzymatic decomposition and reduction of these metabolites. Unlike the classic L-arginine-nitric oxide synthase (NOS) pathway, which is dependent on enzymatic activity and often impaired in patients with endothelial dysfunction, this photochemical pathway is entirely independent of NOS. The UVA radiation induces the homolytic cleavage of the S-N bond in RSNOs and the reduction of nitrite to bioactive nitric oxide gas.

Once liberated, this gaseous NO diffuses through the interstitial fluid and enters the dermal sub-capillary plexus. Upon entering the systemic vasculature, it facilitates the activation of soluble guanylyl cyclase (sGC) in vascular smooth muscle cells. This catalyst converts guanosine triphosphate (GTP) into cyclic guanosine monophosphate (cGMP), which subsequently lowers intracellular calcium levels, inducing profound vasodilation. The resulting reduction in peripheral vascular resistance leads to a measurable decrease in mean arterial pressure (MAP).

Crucially, the 2014 study published in the *Journal of Investigative Dermatology* demonstrated that this BP-lowering effect occurs independently of Vitamin D synthesis, which is driven by UVB radiation. Experimental data showed that when subjects were exposed to UVA doses equivalent to approximately 30 minutes of natural UK summer sunlight, systolic blood pressure dropped significantly, with effects persisting long after the cessation of exposure. This suggests that the skin acts as a massive 'photochemical capacitor,' charging during solar exposure and discharging bioactive nitrogen species into the blood. In the UK context, where hypertension affects one in four adults, understanding this mechanism is vital; it suggests that the seasonal fluctuations in blood pressure observed in the British population are not merely a result of temperature-induced vasoconstriction, but a direct consequence of reduced UVA-mediated NO bioavailability during the winter months. INNERSTANDIN posits that the suppression of this endogenous nitric oxide release via chronic sun avoidance may be a neglected risk factor in the pathogenesis of cardiovascular disease.

Mechanisms at the Cellular Level

To truly INNERSTANDIN the haemodynamic consequences of solar exposure, one must look past the epidermis and into the biochemical transmutations occurring within the dermal vasculature. While conventional medicine has long focused on the renin-angiotensin-aldosterone system (RAAS) and dietary sodium as the primary levers of blood pressure regulation, photobiology reveals a sophisticated, skin-centric mechanism of systemic control. The human skin acts as a massive bioreactor and storage depot for nitric oxide (NO) metabolites, specifically nitrite ($NO_2^-$) and S-nitrosothiols (RSNOs). Crucially, the concentration of these NO species in the cutaneous tissue is nearly tenfold higher than that found in the systemic circulation.

The primary driver of this regulatory pathway is Ultraviolet A (UVA) radiation (315–400 nm). Unlike UVB, which is largely absorbed in the superficial epidermis to synthesise Vitamin D, UVA photons possess the wavelength necessary to penetrate into the deeper dermis, where the majority of the cutaneous microvasculature resides. At the cellular level, this process is defined by the non-enzymatic photodissociation of pre-existing NO stores. Research led by the University of Southampton and the University of Edinburgh (Feelisch et al., 2014, *Journal of Investigative Dermatology*) has demonstrated that UVA irradiation triggers the reductive decomposition of cutaneous nitrate ($NO_3^-$) and nitrite into bioactive nitric oxide gas.

This mechanism is distinct from the endogenous production of NO via endothelial nitric oxide synthase (eNOS). While eNOS activity is often impaired in patients with metabolic dysfunction or oxidative stress, the UVA-mediated release of NO is a purely photochemical reaction, bypassing the need for enzymatic cofactors. Upon liberation, this dermal NO diffuses into the underlying vascular smooth muscle cells. Here, it activates the enzyme soluble guanylate cyclase (sGC), which facilitates the conversion of guanosine triphosphate (GTP) into cyclic guanosine monophosphate (cGMP). The subsequent rise in cGMP levels prompts a reduction in intracellular calcium concentrations, leading to profound vasorelaxation and a reduction in total peripheral resistance.

The systemic impact is not merely localised to the site of irradiation. The newly mobilised NO and its stabilised derivatives enter the systemic circulation, where they exert a vasodilatory effect across the entire arterial tree. Clinical trials conducted in the UK context—where solar scarcity is a significant public health factor—have shown that sub-erythemal doses of UVA (equivalent to approximately 30 minutes of peak summer sunlight) result in a significant and sustained reduction in systolic blood pressure. This evidence suggests that the skin functions as a light-dependent endocrine organ, modulating systemic cardiovascular tone in direct response to the photobiological environment, a truth that necessitates a radical re-evaluation of current photoprotection guidelines.

Environmental Threats and Biological Disruptors

The cutaneous-systemic axis of nitric oxide (NO) homeostasis is not merely a passive biological happenstance; it is a finely tuned evolutionary mechanism reliant upon specific electromagnetic triggers. Within the dermal layers, significant stores of photolabile nitric oxide derivatives—primarily nitrite and S-nitrosothiols (RSNOs)—await liberation. When UVA photons (320–400 nm) penetrate the papillary dermis, they initiate a non-enzymatic reductive process, mobilising these stores into the systemic circulation. This facilitates profound vasodilation and a subsequent reduction in systolic blood pressure (SBP), a phenomenon rigorously documented in seminal research from the University of Southampton and published in *The Journal of Investigative Dermatology*. However, this vital physiological pathway is currently under siege by a suite of modern environmental disruptors and reductive public health paradigms.

The most pervasive biological disruptor to this pathway is the ubiquitous and often indiscriminate application of high-SPF sunscreens. While designed to mitigate DNA damage and erythema, these chemical and mineral barriers are non-selective in their filtration. By truncating the UVA flux reaching the dermis, they effectively sequester the body’s endogenous NO stores, preventing the photo-induced vasodilation that serves as a natural check against hypertension. In the UK context, where cardiovascular disease remains a primary cause of mortality, the dogmatic insistence on total UV blockage represents a significant epidemiological oversight. At INNERSTANDIN, we scrutinise the evidence suggesting that for every skin cancer death potentially prevented by total UV avoidance, a far greater number of lives may be lost to the consequences of chronic hypertension and associated ischaemic heart disease due to "optical malnutrition."

Furthermore, the "biological indoorisation" of the British populace—characterised by an estimated 90% of time spent within artificial enclosures—acts as a systemic disruptor. Standard architectural glazing (soda-lime glass) is highly opaque to the UVA spectrum required for RSNO cleavage. This creates a state of chronic deprivation where the biological machinery for blood pressure regulation is starved of its primary environmental catalyst. This is further exacerbated in urban centres like London, Manchester, and Glasgow, where elevated aerosol optical depth (AOD) due to nitrogen dioxide (NO2) and particulate matter (PM2.5) further attenuates the ground-level UV flux. These pollutants do not merely damage the lungs; they filter the very wavelengths necessary for the skin to regulate the heart.

Compounding this is the shift toward narrow-spectrum artificial illumination. Modern LED and fluorescent systems, which dominate UK workplaces and homes, are devoid of the requisite UV frequencies, offering a sterile spectral environment that fails to trigger cutaneous NO release. Research indicates that without specific UVA-induced activation of the dermal stores, enzymatic pathways—such as endothelial nitric oxide synthase (eNOS)—are often insufficient to maintain optimal vascular tone, particularly in ageing populations where enzymatic efficiency is naturally diminished. This environmental mismatch between our evolutionary requirement for sunlight and our modern, shielded existence constitutes a silent, systemic threat to global haemodynamic stability.

The Cascade: From Exposure to Disease

The integumentary system serves as more than a mere physical barrier; it functions as a colossal, light-activated reservoir for bioactive nitrogen oxides, a fact frequently marginalised in conventional clinical cardiovascular models. While the L-arginine-nitric oxide synthase (NOS) pathway is the primary focus of pharmacological interventions for hypertension, INNERSTANDIN identifies a secondary, non-enzymatic cascade initiated by ultraviolet A (UVA) radiation (315–400 nm) that is critical for systemic haemodynamic homeostasis. The dermis and epidermis sequester inorganic nitrate ($NO_3^-$) and nitrite ($NO_2^-$) at concentrations significantly higher than those found in the systemic circulation. Upon irradiation, UVA triggers the photochemical reduction of these cutaneous stores, alongside the photolysis of S-nitrosothiols and nitrated proteins, effectively liberating free nitric oxide (NO) into the dermal microvasculature.

This photochemical liberation bypasses the traditional constraints of enzymatic NO production, which is often impaired in patients with endothelial dysfunction. Research published in the *Journal of Investigative Dermatology* (Liu et al., 2014) demonstrates that exposure to UVA at levels equivalent to 30 minutes of Mediterranean sunlight induces a significant drop in systolic blood pressure (SBP) by approximately 2–5 mmHg. Though seemingly modest, on a population-wide scale—particularly within the UK's ageing demographic—such a reduction correlates with a 7% decrease in the risk of ischaemic heart disease and a 10% reduction in stroke mortality. The mechanism is predicated on the diffusion of NO from the superficial layers of the skin into the sub-papillary plexus, where it interacts with the vascular smooth muscle cells. This interaction activates soluble guanylyl cyclase (sGC), increasing intracellular cyclic guanosine monophosphate (cGMP) and culminating in profound vasodilation and a reduction in total peripheral resistance.

The systemic implications of this cascade extend beyond acute vasodilation. Chronic sunlight deprivation, a pervasive issue in high-latitude regions such as the United Kingdom, results in a persistent state of dermal nitrogen oxide sequestration. When these stores remain inert due to insufficient UVA exposure, the compensatory burden shifts entirely to the endogenous NOS pathway. In the presence of systemic inflammation or oxidative stress, this pathway is frequently compromised, leading to a state of functional NO deficiency. The "disease" in this cascade is not merely hypertension, but a systemic vascular maladaptation. Evidence suggests that the seasonal variation in blood pressure observed in the UK—where SBP rises significantly during winter months—is not solely a thermoregulatory response to cold, but a direct consequence of the loss of UVA-mediated NO bioavailability. By neglecting the photobiological imperative of the skin-vasculature axis, modern lifestyle patterns have effectively severed a primal link between the solar environment and arterial health, contributing to the global burden of essential hypertension.

What the Mainstream Narrative Omits

The prevailing public health discourse in the United Kingdom has, for decades, operated under a reductionist paradigm that views ultraviolet (UV) radiation almost exclusively through the lens of DNA damage and photocarcinogenesis. While the risks of melanoma and non-melanoma skin cancers are well-documented, this narrow focus has birthed a significant cognitive dissonance in clinical guidance, effectively ignoring a robust body of evidence regarding the systemic cardiovascular benefits of UVA exposure. At INNERSTANDIN, we recognise that the mainstream narrative fails to account for the evolutionary trade-off between UV-induced cutaneous damage and the life-preserving reduction in systemic blood pressure facilitated by nitric oxide (NO) mobilisation.

Contemporary research, most notably the pioneering work of Professor Richard Weller and his team at the University of Edinburgh, has elucidated a nitric oxide synthase (NOS)-independent mechanism for vasodilation. Unlike the enzymatic production of NO in the vascular endothelium, the skin acts as a massive reservoir for nitrogen oxides, sequestering these molecules as S-nitrosothiols, nitrate, and nitrite. When the skin is irradiated with UVA (specifically within the 320–400 nm range), these photolabile species undergo a reductive decomposition, releasing bioactive NO into the systemic circulation. This process occurs independently of the UVB-Vitamin D pathway, yet it is routinely omitted from dermatological warnings that advocate for total UV avoidance or the indiscriminate use of broad-spectrum SPF.

Data published in the *Journal of Investigative Dermatology* (2014) demonstrated that UVA exposure equivalent to 30 minutes of Mediterranean sunlight significantly lowered systolic blood pressure in healthy volunteers, an effect that persisted well beyond the cessation of irradiation. This vasodilation reduces total peripheral resistance, directly impacting cardiovascular mortality—a leading cause of death in the UK that dwarfs the mortality rates of skin cancer. For a deeper INNERSTANDIN of human physiology, one must acknowledge that the systemic benefits of UVA-induced NO release may actually outweigh the risks of skin cancer in populations with low UV exposure.

Furthermore, the mainstream narrative often conflates UV-induced erythema with damage, failing to mention that the cutaneous NOx stores require specific photonic energies to liberate NO into the bloodstream. By ignoring this photobiological reality, current guidelines may be inadvertently contributing to the high prevalence of hypertension in the British population. The "sun-avoidance" culture fails to address the fact that all-cause mortality is significantly higher in individuals who avoid sun exposure compared to those with the highest exposure levels, as evidenced by large-scale longitudinal studies in Scandinavia. The biochemical reality is clear: the skin is not merely a barrier, but a complex endocrine organ that utilizes UVA radiation to regulate cardiovascular tone and systemic health.

The UK Context

The geographical disposition of the United Kingdom, situated between latitudes 50°N and 60°N, presents a profound biological challenge to cardiovascular homeostasis that extends far beyond the well-documented Vitamin D deficiency. At INNERSTANDIN, we must expose the physiological reality that for a significant portion of the year, the UK population exists in a state of 'photobiological poverty'. While public health discourse focuses almost exclusively on cholecalciferol synthesis, the more immediate haemodynamic consequence of British latitude involves the sequestration of nitric oxide (NO) within the dermal layers, unable to be mobilised by insufficient UVA irradiance.

Empirical evidence, pioneered by the University of Edinburgh (Liu et al., *Journal of Investigative Dermatology*, 2014), demonstrates that the skin contains vast stores of photolabile nitric oxide derivatives—specifically nitrite ($NO_2^-$) and S-nitrosothiols (RSNO)—which are significantly more abundant than the circulating nitrate pool. In the UK context, the seasonal fluctuation in UVA (320–400 nm) correlates precisely with systemic blood pressure variations. During the British winter, the zenith angle of the sun prevents adequate UVA penetration to trigger the non-enzymatic release of NO from these cutaneous stores into the systemic circulation. This mechanism is independent of endothelial nitric oxide synthase (eNOS) activity, representing a direct photochemical bypass of internal regulatory bottlenecks.

The systemic impact is staggering: exposure to UVA levels equivalent to those found during a UK summer afternoon has been shown to decrease systolic blood pressure (SBP) by approximately 2–5 mmHg. In a nation where cardiovascular disease remains a leading cause of mortality, this 'solar-driven vasodilation' is a critical, yet overlooked, metric. Research published in *The Lancet* and various PubMed-indexed trials indicates that even a modest 2 mmHg reduction in SBP at a population level could reduce the incidence of stroke and myocardial infarction by up to 10%.

Furthermore, the INNERSTANDIN perspective highlights a technical paradox: the UK’s obsession with high-factor photoprotection and indoor lifestyles may be inadvertently contributing to the national burden of hypertension. By blocking UVA, we inhibit the mobilisation of the dermal NO pool into the lumen of the cutaneous vasculature, thereby increasing peripheral resistance. This failure to utilise the skin as a light-activated endocrine organ exacerbates the UK’s winter peak in cardiovascular events, suggesting that the 'solar deficit' is a primary environmental driver of British hypertensive pathology. The data demands a paradigm shift in UK photobiology: sunlight is not merely a mutagen to be feared, but a fundamental cardiovascular catalyst.

Protective Measures and Recovery Protocols

The pursuit of optimal cardiovascular health via UVA-mediated nitric oxide (NO) liberation requires a sophisticated calibration of exposure duration and biochemical priming to circumvent the threshold of actinic damage. Research led by Feelisch and colleagues at the University of Southampton (2014) has elucidated that cutaneous stores of nitrogen oxides—specifically nitrate, nitrite, and S-nitrosothiols—are not merely metabolic byproducts but are essential precursors for systemic vasodilation. To optimise this mechanism, the protective protocol begins with the strategic timing of exposure relative to the UK’s latitudinal solar window. Given the specific 320–400 nm wavelength required to trigger the non-enzymatic release of NO from the dermis, INNERSTANDIN identifies that sub-erythemal dosing (exposure below the threshold of visible reddening) is the requisite standard for systemic benefit without inducing significant cyclobutane pyrimidine dimer (CPD) formation.

A robust recovery protocol must address the inevitable generation of reactive oxygen species (ROS) that accompanies UVA-induced NO release. While the liberation of NO reduces systolic blood pressure by approximately 2–5 mmHg, the simultaneous production of superoxide anions can lead to the formation of peroxynitrite, a potent oxidant. To mitigate this, the biological system requires a high density of endogenous antioxidants. Data published in *The Lancet* and various photobiology journals suggest that the pre-loading of the epidermis with dietary polyphenols and systemic l-ascorbic acid can significantly raise the photophotic threshold. Furthermore, the role of the endothelial glycocalyx—the delicate gel-like layer lining the vasculature—is paramount. Protective measures must include the maintenance of this layer through the intake of glucosamine and fucoidans, ensuring that the liberated NO can effectively signal the underlying smooth muscle cells for vasodilation rather than being sequestered by oxidative stress.

Recovery is further enhanced through the synergistic application of Near-Infrared (NIR) light. While UVA mobilises the dermal NO stores, NIR (600–1000 nm) has been shown to stimulate mitochondrial cytochrome c oxidase, enhancing cellular ATP production and accelerating the repair of any minor UVA-induced DNA strand breaks. This 'photobiomodulation' acts as a biological counterweight to UVA, facilitating a systemic state of haemodynamic stability. Within the INNERSTANDIN framework, we also emphasise the 'Nitrate-Nitrite-NO' pathway. For maximum efficacy, individuals should ensure high bioavailability of salivary nitrites via the consumption of inorganic nitrates (such as those found in *Beta vulgaris* or *Eruca vesicaria*), which serves to replenish the dermal reservoirs depleted during UVA exposure. This creates a sustainable cycle of cardiovascular regulation that leverages the solar environment as a primary physiological input rather than a mere environmental stressor. Therefore, the protocol for UVA utilization is one of precision: priming the biochemical substrate, timing the photon flux, and employing infrared recovery to neutralise oxidative debt.

Summary: Key Takeaways

The synthesis of contemporary clinical evidence mandates a rigorous paradigm shift in our understanding of cardiovascular health, positioning cutaneous photobiology as a central regulator of systemic haemodynamics. Investigation, notably the landmark trials by Liu et al. (2014) published in the *Journal of Investigative Dermatology*, confirms that UVA irradiation (320–400 nm) triggers the immediate mobilisation of nitric oxide (NO) from substantial pre-existing stores within the human dermis and epidermis. These cutaneous reservoirs, primarily comprising nitrate, nitrite, and S-nitrosothiols, are uniquely photo-labile; upon exposure, they undergo reductive decomposition to bioactive NO, which subsequently diffuses into the systemic circulation.

This mechanism facilitates potent arterial vasodilation and a statistically significant reduction in systolic blood pressure, a physiological response that operates entirely independently of UVB-mediated Vitamin D synthesis. Within the UK context, where hypertension remains a primary driver of cardiovascular mortality, the implications of these findings are profound. Seasonal blood pressure fluctuations observed in British cohorts correlate precisely with solar UVA availability and zenith angles, suggesting that the prevalence of cardiovascular disease may be exacerbated by the chronic photobiological deficit inherent to high-latitude environments. INNERSTANDIN underscores that the maintenance of vascular tone is not merely a product of dietary or genetic factors, but a photobiological imperative. The dermal-vasculature axis serves as a critical interface where environmental light directly modulates systemic peripheral resistance, highlighting that sunlight is an essential, non-pharmacological regulator of arterial tension and overall cardiovascular resilience.